Sign In
HomeNewsNSLHD cancer experts inform national guidelines

NSLHD cancer experts inform national guidelines

Expert clinician researchers from NSLHD have had a key role in the development of new national guidelines for the treatment of neuroendocrine tumours.

The COSA NET guidelines provide information for oncologists, health care providers and patients regarding the latest evidence-informed practice. 

The new recommendations replace the previous ones drafted more than 10 years ago and reflect the significant advances in neuroendocrine tumour treatment over that time. 

New information has now been produced about Multiple Endocrine Neoplasia 1, familial NET syndromes and information about supportive care.

The guidelines have been developed by Australia’s leading clinical and academic experts, including NSLHD clinicians Drs Nick Pavlakis, Jas Samra, Rory Clifton-Bligh, David Chan and Richie Maher. 

It means patients can have confidence they are receiving the very best care in the world, and their treatment will be in line with the latest international advances
Dr David Chan

Dr Pavlakis said the team contributed to the new guidelines by drawing on its expertise in nuclear medicine, systemic therapies, surgery, interventional radiology and clinical trial experience.

“We are confident the new guidelines will provide tremendously valuable, evidenced-based information in a format which is easy to access and adopt,” he said.

In recent years, Sydney Theranostics North – based at RNSH was named a Neuroendocrine Tumour Centre of Excellence, one of just three centres in the southern hemisphere.

Dr Chan said the accreditation is a testament to the exceptional team of clinicians, surgeons, nurses, allied health professionals and researchers at RNSH.

“It’s a credit to a very large number of teams, from medical oncology, radiology and surgery to genetics, palliative care and nutrition,” he said. 

To access the new guidelines for the treatment of neuroendocrine tumours:

What others found interesting…